Centeno-Schultz Clinic Abstract Accepted by Orthopedic Research Society

By /

Our abstract entitled Clinical Percutaneous Implantation of Autologous, Culture-Expanded MSCs into Peripheral Joints was accepted at the Orthopedic Research Society annual conference in Long beach California (Jan 2011).

Abstract below:

Percutaneous Implantation of Autologous, Culture Expanded Mesenchymal Stem Cells into Peripheral Joints: One Year or Greater Follow-up with a Prospective Control Group

Christopher J. Centeno, Michael Freeman,  John R. Schultz, Michelle Cheever, Stephen Faulkner, Ron Hanson, Sean Kohles

Centeno-Schultz Clinic, Broomfield, CO.


Mesenchymal stem cells (MSCs) show great clinical potential as therapeutic agents in regenerative medicine.  These adult stem cells can be easily isolated from many areas in the body, and many animal studies have demonstrated their multipotency in terms of differentiating into muscle, bone, cartilage, tendon, and various cells of internal organs.  We have previously published on a safety study (n=227) regarding orthopedic use of MSC’s cultured in autologous platelet lysate to treat osteoarthritis (OA)[1], showing a robust safety profile.  In this study, patients underwent percutaneous implantation of MSC’s cultured using the same technique to treat hip and knee OA.


221 sequential knee and hip OA patients undergoing the procedure were prospectively followed using written questionnaires distributed via e-mail or by phone at set outcome time points.   Bone marrow MSC’s were obtained from bone marrow aspirates, isolated, and cultured using an autologous platelet lysate technique.  The cultured cells were re-injected via imaging guidance into either the painful hip or knee.  Pain relief was measured on a Likert scale of -90% to 100% improvement.  A control group was recruited at the same time as the treatment group from patients choosing not to pursue the procedure.


From the knee OA sample treated, 93 patients were male and 42 were female.  The average age of treated knee patients (n=135) was 56.13 +/- 12.38 years and for hip patients it was 56.18 +/- 12.59 years (n=65).  41.4/63.2% of knee patients and 23.8/42.8% of hip patients reported >75%/>50% improvement respectively, see figure 1.  Average reported relief was 53.12% in the knee OA group (n=133 reporting) and 30.35% in the hip OA group (n=42 reporting), there was a significant difference between the groups (p=0.003), see figure 2, with more outcome end-point drop-out in the hip group.  Average reported improvement (n=29) in the control group was -2.75%. During the surveillance period, 4.1% of the knee patients and 21.5% of the hip patients reported undergoing a total arthroplasty procedure or had one planned, despite MSC therapy.

Reported improvement increased over time at the 12 month and 24 month time points in the knee group.  Of note, high Body mass Index (BMI) females (n=23) have a significantly lower proliferation rate (defined as total number of MSCs injected/days in culture) in culture (mean= 0.4358+/- 0.3702) when compared to high BMI males (n=86, mean=1.16+/- 0.916, p=8.813E-8), normal BMI females (n=31, mean= 0.8152+/- 0.6179, p=.007), and normal BMI males (n=32, mean=1.210+/-1.01, p=2.684E-4), see figure 3. Nanogram dexamethasone preconditioning in culture was associated with more improvement (n=82, mean= +53.59% SD=38.69, p=0.039) vs. the group without pre-conditioning (n=76, mean=+39.40%, SD=46.82).


Percutaneous re-implantation of autologous MSC’s was associated with patient reported relief.  There was better improvement in knee vs. hip OA patients and reported relief was significantly better than an untreated prospective control group.  Overweight females suffered from poor proliferation in culture and dexamethasone culture conditioning was associated with better clinical relief.  These findings may have implications for other orthopedic applications involving MSC culture.

Figure 1. The percentage of patients reporting >50% relief and >75% relief for knee and hip groups.

Figure 2. The average percentage relief reported in all knee and hip OA patients.

Figure 3. Proliferation rate comparisons in gender specific patients with varying BMI.


1. Centeno, C.J., et al., Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther, 2010. 5(1): p. 81-93.

NOTE: The hip patients in this sample included some patients with OA and AVN/ON. This data will also be reviewed with the AVN/ON patients taken out of the hip OA group to determine if this changes the outcome for the hip OA group.

Join us for a free Regenexx webinar.
Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile

If you have questions or comments about this blog post, please email us at [email protected]

NOTE: This blog post provides general information to help the reader better understand regenerative medicine, musculoskeletal health, and related subjects. All content provided in this blog, website, or any linked materials, including text, graphics, images, patient profiles, outcomes, and information, are not intended and should not be considered or used as a substitute for medical advice, diagnosis, or treatment. Please always consult with a professional and certified healthcare provider to discuss if a treatment is right for you.

Get Blog Updates by Email

We do not sell, or share your information to third party vendors.

By submitting the form you agree that you’ve read and consent to our Privacy Policy. We may use email, phone, or other electronic means to communicate information about Regenexx.

We will provide information to help you decide whether you want to schedule an evaluation with a Regenexx Physician.

Insurance typically covers evaluations and diagnostic testing (if recommended). Most insurance plans currently do not cover Regenexx Procedures.

Copyright © Regenexx 2021. All rights reserved.



9035 Wadsworth Pkwy #1000
Westminster, CO 80021


*DISCLAIMER: Like all medical procedures, Regenexx® Procedures have a success and failure rate. Patient reviews and testimonials on this site should not be interpreted as a statement on the effectiveness of our treatments for anyone else.

Providers listed on the Regenexx website are for informational purposes only and are not a recommendation from Regenexx for a specific provider or a guarantee of the outcome of any treatment you receive.